A magnetic nanoparticle including a TRPV1 agonist, as well as methods of preparation and use, are described herein. A magnetically responsive pharmaceutical can include a core region having a magnetic nanoparticle (MNPs) and a TRPV1 protein agonist. Further, an exterior coating comprising a polymer can be formed around the core region. The magnetically responsive pharmaceutical can be administered to a recipient and directed to a target region using an external magnetic field.

The present invention discloses the morphology of hollow, double-shelled submicrometer particles generated through a rapid aerosol-based process. The inner shell is an essentially hydrophobic carbon layer of nanoscale dimension (5-20 nm), and the outer shell is a hydrophilic silica layer of approximately 5-40 nm, with the shell thickness being a function of the particle size. The particles are synthesized by exploiting concepts of salt bridging to lock in a surfactant (CTAB) and carbon precursors together with iron species in the interior of a droplet. This deliberate negation of surfactant templating allows a silica shell to form extremely rapidly, sealing in the organic species in the particle interior. Subsequent pyrolysis results in a buildup of internal pressure, forcing carbonaceous species against the silica wall to form an inner shell of carbon. The incorporation of magnetic iron oxide into the shells opens up applications in external stimuli-responsive nanomaterials.

Polyelectrolyte microcapsules, and methods for making and using the polyelectrolyte microcapsules, are described. A method of making polyelectrolyte microcapsules includes forming an “interfacial complexation in emulsion” (ICE), wherein a polyelectrolyte “shell” is formed by complexing two different polyelectrolytes together at an interface between two immiscible fluids. Both hydrophilic and hydrophobic materials can be incorporated into the cores and shells of the polyelectrolyte microcapsules.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases.

The disclosure provides systems for ultrasound-induced thrombolysis with magnetic microbubbles under a rotational/alternating magnetic field, sonothrombolysis systems with magnetic microbubbles and optional nanodroplets for inducing thrombolysis under an acoustic field, and a rotational/alternating magnetic field, and methods of treating patients with blood clots using the sonothrombolysis systems of the present disclosure.

A device is dynamically programmable to generate at least a first magnetic field during a first time interval, and at least a second magnetic field during a second time interval thereby causing the particles exposed to the change in the magnetic field to aggregate to a target region. The device is further dynamically programmable to switch between the first and second magnetic fields for any number of cycles. Optionally, the device includes a multitude of conductors that receive a first current during the first time interval to generate the magnetic field, and a second multitude of conductors that receive a second current during the second time interval to generate the second magnetic field. The second multitude of conductors may be substantially parallel to the first multitude of conductors. A controller disposed within the device is adapted to vary the frequency of switching between the first and second magnetic fields.

The disclosure discloses a Pickering emulsion stabilized by cellulose from ginkgo seed shells and a preparation method thereof, and belongs to the fields of preparation methods of biomass materials and food chemical industry. The disclosure uses ginkgo seed shells as a raw material to obtain high-purity cellulose through hot alkali treatment and sodium chlorite bleaching. After the cellulose is dried, the cellulose is hydrolyzed with sulfuric acid to obtain a cellulose nanocrystal suspension. The suspension is mixed with an oil phase, and the Pickering emulsion is obtained through high-speed shearing and homogeneous emulsification. The disclosure can prepare cellulose nanocrystals with different aspect ratios by adjusting the parameters of high-speed shearing and homogeneous emulsification according to actual production needs. Cellulose nanocrystals with high aspect ratio can be used to prepare stable Pickering emulsions with high oil phase and high viscosity, which can be applied to the fields of food, cosmetics and the like; and cellulose nanocrystals with low aspect ratio can be used to prepare Pickering emulsions with low viscosity and high fluidity, which can to be applied to the fields of food and medicine.

Image-guided microrobotic systems, methods and methods that employ micromotor(s) having imaging agent(s) and cargo in a microcapsule, each micromotor having a partial coating over a reactive particle and/or asymmetrical geometry, when activated the microcapsule disintegrates releasing the micromotor(s) and active propulsion is generated when fluid contacts the reactive particle.

A method of delivering magnetic particles to a target site, including inserting a magnet catheter into a blood vessel; advancing the magnet catheter to a position downstream from the target site; and releasing magnetic particles into the blood vessel upstream of the target site; in which a first portion of the magnetic particles embolize in the blood vessel is disclosed. A system is also disclosed.